

Table 2.23. Case-control studies of HPV prevalence and cancers of the oropharynx and tonsil

Reference, study location	Sites included	No. of cases	No. of controls	Method of detection	HPV prevalence (%)		Odds ratio (95% CI)	Comments/adjustments
					Cases	Controls		
Hansson <i>et al.</i> (2005), Sweden	Oropharynx	46	320	MY09/11 GP5+/GP6+	45.6	0.94	230 (44–1200)	Swabs of tumours (cases) and tonsillar fossa and mouthwash Adjusted for tobacco and alcohol
D'Souza <i>et al.</i> (2007), USA	Oropharynx	100	200	MY09/11 PCR	37.0	6.0	12.3 (5.4–26.4) multivariate adjustment L1 Antibodies HPV16 32.2 (14.6–71.3) E6 E7 antibodies HPV16 58.4 (24.3–138.3)	Saline oral rinse and cytology brush of posterior oropharyngeal wall Formelin fixed biopsies HPV 16 DNA in 72% of tumor biopsies Adjusted for age, sex, tobacco, alcohol, dentition, toothbrushing and family history
Pintos <i>et al.</i> (2008) Canada	Palatine tonsil Base of tongue	12	123	PGMY09/11 Line blot HPV	42.8	4.7	19.3 (2.3–159.5) (oncogenic types)	Adjusted for age, sex schooling, race, religion, language, smoking, alcohol